<SEC-DOCUMENT>0001193125-25-274596.txt : 20251110
<SEC-HEADER>0001193125-25-274596.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110172438
ACCESSION NUMBER:		0001193125-25-274596
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251108
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Intellia Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001652130
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				364785571
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37766
		FILM NUMBER:		251467468

	BUSINESS ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-285-6200

	MAIL ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d12611d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ntla="http://intelliatx.com/20251108" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-368">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-11-08_to_2025-11-08">0001652130</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="ntla-20251108.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-11-08_to_2025-11-08"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001652130</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-08</xbrli:startDate> <xbrli:endDate>2025-11-08</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-379">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-11-08_to_2025-11-08" format="ixt:datemonthdayyearen" id="ixv-380">November&#160;8, 2025</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-381">INTELLIA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-11-08_to_2025-11-08" format="ixt-sec:stateprovnameen" id="ixv-382">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-383">001-37766</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-384">36-4785571</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-385">40 Erie Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-386">Suite 130</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-387">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-11-08_to_2025-11-08" format="ixt-sec:stateprovnameen" id="ixv-388">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-389">02139</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-390">(857)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-391">285-6200</ix:nonNumeric></span></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-11-08_to_2025-11-08" format="ixt-sec:boolballotbox" id="ixv-392">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-11-08_to_2025-11-08" format="ixt-sec:boolballotbox" id="ixv-393">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-11-08_to_2025-11-08" format="ixt-sec:boolballotbox" id="ixv-394">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-11-08_to_2025-11-08" format="ixt-sec:boolballotbox" id="ixv-395">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-396">Common Stock (Par Value $0.0001)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-397">NTLA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-11-08_to_2025-11-08" format="ixt-sec:exchnameen" id="ixv-398">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#8201;240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-11-08_to_2025-11-08" format="ixt-sec:boolballotbox" id="ixv-399">&#9744;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01 Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;8, 2025, Intellia Therapeutics, Inc.&#160;(the &#8220;Company&#8221;) issued a press release titled &#8220;Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema.&#8221; A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2025, the Company issued a press release titled &#8220;Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran <span style="white-space:nowrap">(nex-z)</span> in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy.&#8221; A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information under this Item 7.01, including Exhibits 99.1 and 99.2 hereto, are being furnished herewith and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 1/2 Data for Lonvoguran Ziclumeran </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;8, 2025, the Company announced positive new clinical data from the ongoing Phase 1/2 trial of lonvoguran ziclumeran (&#8220;lonvo-z,&#8221; also known as NTLA-2002) in patients with hereditary angioedema (&#8220;HAE&#8221;). Lonvo-z is an investigational <span style="font-style:italic">in vivo</span> CRISPR-based gene editing therapy that is currently in development as a <span style="white-space:nowrap">one-time</span> treatment for HAE. The global Phase 1/2 trial is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II HAE. These results were shared in an oral presentation at the American College of Allergy, Asthma&#160;&amp; Immunology 2025 Annual Scientific Meeting in Orlando, Florida on November&#160;8, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical data presented on November&#160;8 was based on a pooled analysis of all 32 patients who have received a <span style="white-space:nowrap">one-time</span> 50 mg treatment of lonvo-z via intravenous infusion in the Phase 1/2 trial. Of the 32 patients, 15 had initially received the 50 mg dose at study day 1 (four in Phase 1 and 11 in Phase 2) and 17 were treated after unblinding of the Phase 2 clinical trial for the primary analysis (11 had originally received a 25 mg dose of lonvo-z, which was determined to be a suboptimal dose, and six had previously received placebo). The data <span style="white-space:nowrap">cut-off</span> date for the analysis was August&#160;29, 2025.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deep, stable and durable reductions in plasma kallikrein were observed in all patients, with a mean reduction of 89% at month 24. Among the 32 patients, 31 (97%) were both attack-free and long-term prophylaxis (&#8220;LTP&#8221;)-free as of the data cutoff date, with 24 (75%) being attack-free and <span style="white-space:nowrap">LTP-free</span> for at least seven months (up to 32 months for patients with the longest <span style="white-space:nowrap">follow-up).</span> Of the 11 patients who initially received the 50 mg dose of lonvo-z in Phase 2, 10 were attack-free and <span style="white-space:nowrap">LTP-free</span> (nine for <span style="white-space:nowrap">7-32</span> months and one for &lt;6 months). The one patient who was not attack-free and <span style="white-space:nowrap">LTP-free</span> as of the data cutoff date had a 59% reduction from baseline in their monthly attack rate.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a 50 mg dose, a well-tolerated safety profile was observed in the Phase 1/2 trial for up to three years of <span style="white-space:nowrap">follow-up</span> with no long-term risks identified. The most frequent treatment-emergent adverse events (&#8220;TEAEs&#8221;) within 28 days of infusion were infusion-related reactions, fatigue and headache. The most frequent TEAEs reported &#8805;28 days after infusion up to long-term <span style="white-space:nowrap">follow-up</span> (&#8220;LTFU&#8221;) were nasopharyngitis, upper respiratory tract infection, back pain, arthralgia and <span style="white-space:nowrap">COVID-19.</span> A single Grade 2 AST elevation was reported among all patients in the Phase 1/2 trial who received a 50&#160;mg dose of lonvo-z. This event had an onset at study day 1 and spontaneously resolved by study day 4 in a patient previously treated with lonvo-z 25&#160;mg. Safety of the 50&#160;mg dose after patients received the suboptimal dose (25&#160;mg) was consistent with the overall clinical trial population. There were no clinically significant shifts in liver enzymes or coagulation parameters. One serious adverse event (&#8220;SAE&#8221;), a pulmonary embolism, was observed in a patient with multiple risk factors one year after the infusion, and the event resolved without sequelae. In LTFU (n=17), there were no SAEs or TEAEs reported with lonvo-z 50&#160;mg, as of the data cutoff date.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">one-time</span> 50 mg treatment of lonvo-z is being further evaluated in patients with HAE in the ongoing global Phase 3 HAELO clinical trial, which completed enrollment in September 2025.&#160;The Company expects to report topline data from the HAELO Phase 3 trial by <span style="white-space:nowrap">mid-2026.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 1 Data for Nexiguran Ziclumeran </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2025, the Company announced positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran <span style="white-space:nowrap">(&#8220;nex-z,&#8221;</span> also known as NTLA-2001) in patients with transthyretin (&#8220;ATTR&#8221;) amyloidosis with cardiomyopathy <span style="white-space:nowrap">(&#8220;ATTR-CM&#8221;).</span> <span style="white-space:nowrap">Nex-z</span> is an investigational <span style="font-style:italic">in vivo</span> CRISPR-based gene editing therapy in development as a <span style="white-space:nowrap">one-time</span> treatment for ATTR </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amyloidosis. The Phase 1 clinical trial is an open-label, <span style="white-space:nowrap">two-part</span> trial evaluating the safety and efficacy of <span style="white-space:nowrap">nex-z</span> in patients with <span style="white-space:nowrap">ATTR-CM.</span> These results were shared in a late-breaking oral presentation at the American Heart Association Scientific Sessions 2025 in New Orleans, Louisiana on November&#160;10, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1 trial enrolled 36 patients, a high proportion of whom had advanced disease at baseline (50% classified as New York Heart Association (&#8220;NYHA&#8221;) Class&#160;III and 31% with variant <span style="white-space:nowrap">ATTR-CM).</span> The data <span style="white-space:nowrap">cut-off</span> date for the clinical data presented on November&#160;10 was August&#160;23, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Across all patients in the Phase 1 trial, a <span style="white-space:nowrap">one-time</span> treatment of <span style="white-space:nowrap">nex-z</span> led to consistently rapid, deep and sustained serum TTR reduction, regardless of baseline levels, through the data <span style="white-space:nowrap">cut-off</span> date. All patients in the Phase 1 trial continued to show a sustained response with no evidence of a waning effect over time. Among the 9 patients who reached 36 months of <span style="white-space:nowrap">follow-up,</span> the mean serum TTR reduction was 87% (mean absolute serum TTR level of 22.9&#160;&#181;g/mL [Mean 95% CI, 16.0 to 29.8]), consistent with the overall cohort at month 24. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients dosed with <span style="white-space:nowrap">nex-z</span> in the Phase 1 trial continued to show evidence of disease stabilization or improvement at month 24 compared to baseline. Evaluation was based on multiple markers of cardiomyopathy, including <span style="white-space:nowrap">N-terminal</span> <span style="white-space:nowrap"><span style="white-space:nowrap">pro-B-type</span></span> natriuretic peptide <span style="white-space:nowrap">(&#8220;NT-proBNP&#8221;),</span> high sensitivity Troponin T <span style="white-space:nowrap">(&#8220;hs-Troponin</span> T&#8221;), <span style="white-space:nowrap">6-minute</span> walk test (&#8220;6MWT&#8221;), Kansas City Cardiomyopathy Questionnaire (&#8220;KCCQ&#8221;), and echocardiographic measures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At 24 months, <span style="white-space:nowrap">NT-proBNP</span> and <span style="white-space:nowrap">hs-Troponin</span> T, which are markers known to be associated with disease progression, showed stability or improvement in 70% and 85% of patients in the Phase 1 trial, respectively. Preservation of functional status, as measured by 6MWT, was observed with 69% of patients either showing stability or improvement. Notably, 81% of patients were stable or improved in their NYHA classification at 24 months, including improvement in 83%&#160;of patients with NYHA Class&#160;III. There also was evidence of benefit in quality of life, regardless of NYHA Class&#160;at baseline as assessed by KCCQ. Assessment of cardiac structure with echocardiography, showed a similar pattern of stability with limited progression of cardiac remodeling at 24 months. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, findings from a mortality assessment were presented. This <span style="white-space:nowrap">post-hoc</span> analysis was conducted on a cohort of 1,792 <span style="white-space:nowrap">ATTR-CM</span> patients from the National Amyloidosis Center whose baseline characteristics were matched to those of the Phase 1 <span style="white-space:nowrap">nex-z</span> population. The analysis showed patients receiving a <span style="white-space:nowrap">one-time</span> treatment with <span style="white-space:nowrap">nex-z</span> in the Phase 1 trial had an <span style="white-space:nowrap">all-cause</span> mortality rate of 3.9 per 100 patient-years, while the matched cohort had an <span style="white-space:nowrap">all-cause</span> mortality rate of 12.7 per 100 patient-years (HR 0.27, p=0.009). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Nex-z</span> was generally well tolerated across all patients in the Phase 1 clinical trial. The most commonly reported treatment-related adverse events were infusion-related reactions and transaminase elevations. In this Phase 1 population, liver enzyme elevations did not exceed Grade 2. Through the long-term <span style="white-space:nowrap">follow-up</span> evaluation, as of the data <span style="white-space:nowrap">cut-off</span> date, including patients who reached 44 months, any event leading to death (n=4) was related to the progression of the patients&#8217; underlying cardiovascular disease, consistent with what is expected for this patient population. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Nex-z</span> is being further evaluated in patients with ATTR amyloidosis in the ongoing global Phase 3 MAGNITUDE and <span style="white-space:nowrap">MANGITUDE-2</span> clinical trials for <span style="white-space:nowrap">ATTR-CM</span> and hereditary ATTR amyloidosis with polyneuropathy, respectively. On October&#160;29, 2025, the United States Food and Drug Administration placed a clinical hold on the investigational new drug applications for the MAGNITUDE and <span style="white-space:nowrap">MAGNITUDE-2</span> trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K&#160;and&#160;certain</span> of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia&#8217;s beliefs and expectations regarding: the safety, tolerability, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or &#8220;lonvo-z&#8221; (f/k/a NTLA-2002) for hereditary angioedema (&#8220;HAE&#8221;) and nexiguran ziclumeran or <span style="white-space:nowrap">&#8220;nex-z&#8221;</span> (f/k/a NTLA-2001) for transthyretin (&#8220;ATTR&#8221;) amyloidosis, including the ability to successfully complete its global Phase 3 HAELO study of lonvo-z for HAE and to address the clinical hold that the United States Food and Drug Administration (&#8220;FDA&#8221;) placed on the investigational new drug (&#8220;IND&#8221;) applications for its global Phase 3 MAGNITUDE study of <span style="white-space:nowrap">nex-z</span> for ATTR amyloidosis with cardiomyopathy <span style="white-space:nowrap">(&#8220;ATTR-CM&#8221;)</span> and its global Phase 3 <span style="white-space:nowrap">MAGNITUDE-2</span> study for hereditary ATTR amyloidosis with polyneuropathy <span style="white-space:nowrap">(&#8220;ATTRv-PN&#8221;)</span> to resume the MAGNITUDE and <span style="white-space:nowrap">MAGNITUDE-2</span> clinical trials; its ability to present a topline data readout from the HAELO study by mid-2026; lonvo-z&#8217;s potential to become a <span style="white-space:nowrap">one-time</span> treatment for HAE; and <span style="white-space:nowrap">nex-z&#8217;s</span> potential to become a <span style="white-space:nowrap">one-time</span> treatment for ATTR amyloidosis. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this current report on Form <span style="white-space:nowrap">8-K</span> are based on management&#8217;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia&#8217;s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia&#8217;s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies&#8217; evaluation of regulatory filings and other information related to our product candidates, including lonvo-z and <span style="white-space:nowrap">nex-z;</span> uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including risks related to our ability to complete the Phase 3 HAELO study for HAE, present a topline data readout from the HAELO study by <span style="white-space:nowrap">mid-2026,</span> generate data to support lonvo-z&#8217;s potential to be a <span style="white-space:nowrap">one-time</span> treatment for HAE, address the clinical hold that the FDA placed on the IND applications for the MAGNITUDE Phase 3 study for <span style="white-space:nowrap">ATTR-CM</span> and the <span style="white-space:nowrap">MAGNITUDE-2</span> Phase 3 study for <span style="white-space:nowrap">ATTRv-PN</span> and to resume those clinical trials; the risk that any one or more of Intellia&#8217;s product candidates, including lonvo-z and <span style="white-space:nowrap">nex-z,</span> will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia&#8217;s other product candidates; and risks related to Intellia&#8217;s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia&#8217;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in Intellia&#8217;s most recent annual report on <span style="white-space:nowrap">Form&#160;10-K</span> and quarterly report on <span style="white-space:nowrap">Form&#160;10-Q,</span> as well as discussions of potential risks, uncertainties, and other important factors in Intellia&#8217;s other filings with the Securities and Exchange Commission. All information in this current report on <span style="white-space:nowrap">Form&#160;8-K</span> is as of the date of the report, and Intellia undertakes no duty to update this information unless required by law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d12611dex991.htm">Press Release dated November 8, 2025 titled &#8220;Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angiodema&#8221;</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d12611dex992.htm">Press Release dated November 10, 2025 titled &#8220;Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy&#8221;</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">Intellia Therapeutics, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: November&#160;10, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John M. Leonard</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name: John M. Leonard</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title: Chief Executive Officer and President</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d12611dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12611g1111003715793.jpg" ALT="LOGO" STYLE="width:6.57569in;height:1.15556in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;8, 2025 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Deep, stable and durable reductions in kallikrein observed </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff:</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>31 (97%) were attack-free and long-term prophylaxis (LTP)-free </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>24 (75%) were attack-free and <FONT STYLE="white-space:nowrap">LTP-free</FONT> for at least seven months (up
to 32 months)</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Among the 11 patients who originally received a 50 mg dose in Phase 2, 10 were attack-free and <FONT
STYLE="white-space:nowrap">LTP-free</FONT> </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Continue to observe a well-tolerated safety profile with up to three years of patient <FONT
STYLE="white-space:nowrap">follow-up</FONT> and no new long-term risks identified </I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE)
&#8211; Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented positive clinical data from a pooled analysis of all patients who
received a 50 milligram (mg) dose of lonvo-z in the company&#8217;s ongoing Phase 1/2 clinical trial in patients with hereditary angioedema (HAE). These results were shared in an oral presentation today at the American College of Allergy,
Asthma&nbsp;&amp; Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Today&#8217;s data further support our belief that
lonvo-z could completely redefine the HAE treatment landscape,&#8221; said Intellia President and Chief Executive Officer John Leonard, M.D. &#8220;With up to three years of <FONT STYLE="white-space:nowrap">follow-up,</FONT> the vast majority of
patients who received a <FONT STYLE="white-space:nowrap">one-time</FONT> 50 mg dose of lonvo-z &#8211; including 10 of our original 11 patients who received this dose in Phase 2 &#8211; were both attack-free and
<FONT STYLE="white-space:nowrap">LTP-free</FONT> as of the data cutoff. We are looking forward to our approaching topline readout from our Phase 3 HAELO clinical trial by <FONT STYLE="white-space:nowrap">mid-2026.&#8221;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Hereditary angioedema is a condition with significant burden that is marked by the unpredictable nature of when the next attack could occur, the
painful and often prolonged swellings themselves as well as the need for lifelong treatment,&#8221; said Dr.&nbsp;Danny Cohn, M.D., Ph.D., Internist, Department of Vascular Medicine, Amsterdam University Medical Center. &#8220;The data presented
today offer hope that lonvo-z could significantly reduce or remove those burdens for many patients via a <FONT STYLE="white-space:nowrap">one-time</FONT> treatment. I am eagerly awaiting results from the ongoing HAELO Phase 3 clinical trial.&#8221;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 1 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pooled Phase 1/2 Analysis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia&#8217;s global Phase 1/2 clinical trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of lonvo-z in adults with HAE
Types I or II. Today&#8217;s presentation was based on a pooled analysis of all 32 patients who have received a <FONT STYLE="white-space:nowrap">one-time</FONT> 50 mg treatment of lonvo-z via intravenous infusion in the Phase 1/2 trial. Of the 32
patients, 15 had initially received the 50 mg dose at study Day 1 (four in Phase 1 and 11 in Phase 2) and 17 were treated after unblinding of the Phase 2 clinical trial for the primary analysis (11 had originally received a 25 mg dose of lonvo-z,
which was determined to be a suboptimal dose, and six had previously received placebo). The data <FONT STYLE="white-space:nowrap">cut-off</FONT> for the analysis was August&nbsp;29, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deep, stable and durable reductions in plasma kallikrein were observed in all patients, with a mean reduction of 89% at month 24. Among the 32 patients, 31
(97%) were both attack-free and <FONT STYLE="white-space:nowrap">LTP-free</FONT> as of the data cutoff, with 24 (75%) being attack-free and <FONT STYLE="white-space:nowrap">LTP-free</FONT> for at least seven months (up to 32 months for patients with
the longest <FONT STYLE="white-space:nowrap">follow-up).</FONT> Of the 11 patients who initially received the 50 mg dose of lonvo-z in Phase 2, 10 were attack-free and <FONT STYLE="white-space:nowrap">LTP-free</FONT> (nine for <FONT
STYLE="white-space:nowrap">7-32</FONT> months and one for &lt;6 months). The one patient who was not attack-free and <FONT STYLE="white-space:nowrap">LTP-free</FONT> as of the data cutoff had a 59% reduction from baseline in their monthly attack
rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safety </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a 50 mg dose, a well-tolerated
safety profile was observed for up to three years of <FONT STYLE="white-space:nowrap">follow-up</FONT> with no long-term risks identified. The most frequent treatment-emergent adverse events (TEAEs) within 28 days of infusion were infusion-related
reactions, fatigue and headache. The most frequent TEAEs reported &#8805;28 days after infusion up to long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> (LTFU) were nasopharyngitis, upper respiratory tract infection, back pain, arthralgia
and <FONT STYLE="white-space:nowrap">COVID-19.</FONT> A single Grade 2 AST elevation was reported among all patients who received a 50 mg dose of lonvo-z. This event had an onset at Day 1 and spontaneously resolved by Day 4 in a patient previously
treated with lonvo-z 25 mg. Safety of the 50 mg dose after patients received the suboptimal dose (25 mg) was consistent with the overall clinical trial population. There were no clinically significant shifts in liver enzymes or coagulation
parameters. One serious adverse event (SAE), a pulmonary embolism, was observed in a patient with multiple risk factors one year after the infusion, and the event resolved without sequelae. In LTFU (n=17), there were no SAEs or TEAEs reported with
50 mg of lonvo-z, as of the data cutoff. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">one-time</FONT> 50 mg treatment of lonvo-z is being further evaluated in
patients with HAE in the ongoing global Phase 3 HAELO clinical trial that completed enrollment in September 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACAAI data presentation will be
available on the Scientific Publications&nbsp;&amp; Presentations section of <U>intelliatx.com</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 2 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Lonvoguran Ziclumeran (lonvo-z, formerly known as NTLA-2002) Clinical Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia&#8217;s ongoing Phase 1/2 clinical trial is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema
(HAE). The Phase 1 portion is an international, open-label trial designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the trial. Enrollment in both portions of the Phase 1/2 trial is complete.
Intellia completed enrollment in the global Phase 3, randomized, double-blind, placebo-controlled HAELO clinical trial in September of 2025. Visit <U>clinicaltrials.gov</U> (NCT05120830) for more details. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lonvo-z </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Based on Nobel <FONT
STYLE="white-space:nowrap">Prize-winning</FONT> CRISPR/Cas9 technology, lonvo-z has the potential to become the first <FONT STYLE="white-space:nowrap">one-time</FONT> treatment for hereditary angioedema (HAE). Lonvo-z is an investigational <I>in
vivo</I> CRISPR-based gene editing therapy that is currently being investigated in HAELO, a Phase 3 clinical trial in HAE, and is designed to prevent HAE attacks by inactivating the <I>kallikrein B1</I> (<I>KLKB1</I>) gene, which encodes for
prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory
designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the
European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Intellia Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc.&nbsp;(NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based
therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicines that address important unmet
medical needs and advance the treatment paradigm for patients. Intellia&#8217;s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full
potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at&nbsp;<U>intelliatx.com</U>&nbsp;and follow us&nbsp;<U>@intelliatx</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
&#8220;forward-looking statements&#8221; of&nbsp;Intellia Therapeutics, Inc.&nbsp;(&#8220;Intellia&#8221; or the &#8220;Company&#8221;) within the meaning of the Private Securities Litigation Reform Act of 1995.&nbsp;These forward-looking statements
include, but are not limited to, express or implied statements regarding Intellia&#8217;s beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or &#8220;lonvo-z&#8221;
(f/k/a NTLA-2002) for hereditary angioedema (&#8220;HAE&#8221;), including the ability to successfully complete its global Phase 3 HAELO study and to present a topline data readout from the HAELO study by
<FONT STYLE="white-space:nowrap">mid-2026;</FONT> and lonvo-z&#8217;s potential to significantly reduce or remove burdens for patients with HAE and to become the first <FONT STYLE="white-space:nowrap">one-time</FONT> treatment for HAE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 3 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this press release are based on management&#8217;s current expectations
and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.&nbsp;These risks and
uncertainties include, but are not limited to: risks related to Intellia&#8217;s ability to protect and maintain its intellectual property position; risks related to Intellia&#8217;s relationship with third parties, including its contract
manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia&#8217;s ability to protect and maintain its intellectual property position;
risks related to valid third party intellectual property; risks related to Intellia&#8217;s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their
intellectual property position; uncertainties related to regulatory agencies&#8217; evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation
and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE, present a
topline data readout from the HAELO study by <FONT STYLE="white-space:nowrap">mid-2026,</FONT> and generate data to support lonvo-z&#8217;s potential to significantly reduce or remove burdens for patients with HAE via a <FONT
STYLE="white-space:nowrap">one-time</FONT> treatment; the risk that any one or more of Intellia&#8217;s product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical
studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia&#8217;s other product candidates.&nbsp;For a discussion of these and other risks and uncertainties, and
other important factors, any of which could cause Intellia&#8217;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in Intellia&#8217;s most recent annual report of
Form <FONT STYLE="white-space:nowrap">10-K</FONT> and quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in Intellia&#8217;s other filings with
the&nbsp;Securities and Exchange Commission.&nbsp;All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 4 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellia Contacts: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason Fredette </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jason.fredette@intelliatx.com</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media:</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Matt Crenson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ten Bridge Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mcrenson@tenbridgecommunications.com </U></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># #
# </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 5 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d12611dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12611g1111003715793.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cardiomyopathy </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">One-time</FONT> treatment of nex-z led to consistently rapid, deep and
durable reduction in serum TTR through three years of <FONT STYLE="white-space:nowrap">follow-up</FONT></I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Consistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of
NYHA Class, at 24 months compared to baseline</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Longer-term safety data consistent with previously reported Phase 1 data</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on
revolutionizing medicine with CRISPR-based therapies, today announced positive <FONT STYLE="white-space:nowrap">follow-up</FONT> data from the ongoing Phase 1 clinical trial of its investigational product nexiguran ziclumeran (nex-z) in patients
with transthyretin (ATTR) amyloidosis with cardiomyopathy. Results were shared today in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;These longer-term data showed a consistent and durable reduction in TTR and stability or improvement in multiple markers of cardiomyopathy following a
single dose of nex-z,&#8221; said Intellia President and Chief Executive Officer John Leonard, M.D. &#8220;It&#8217;s remarkable that even in patients with advanced heart failure, a population that declines rapidly, disease stabilization or
improvement was observed out to 24 months in a majority of participants. We look forward to seeing how these data mature in longer-term follow up. In addition, we are working diligently to address the ongoing clinical hold the FDA placed on our
MAGNITUDE and <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> Phase 3 clinical trials.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;ATTR amyloidosis is a progressive and fatal
disease, often leaving patients with shortened lifespans and poor quality of life,&#8221; said Julian Gillmore, M.D., Ph.D., Professor of Medicine, National Amyloidosis Center, UCL Division of Medicine, Royal Free Hospital, U.K. &#8220;Today&#8217;s
data support the potential benefit of nex-z and how persistently low levels of serum TTR may translate to improved outcomes and lowered rates of mortality.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1 clinical trial is an open-label, <FONT STYLE="white-space:nowrap">two-part</FONT> trial evaluating the safety and efficacy of nex-z in patients
with ATTR amyloidosis with cardiomyopathy <FONT STYLE="white-space:nowrap">(ATTR-CM).</FONT> The trial enrolled 36 patients, a high proportion of whom had advanced disease at baseline (50% classified as New York Heart Association (NYHA)
Class&nbsp;III and 31% with variant <FONT STYLE="white-space:nowrap">ATTR-CM).</FONT> Data presented today were as of an August&nbsp;23, 2025, data <FONT STYLE="white-space:nowrap">cut-off</FONT> date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 1 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Continuation of Deep and Durable Serum TTR Reduction in Phase 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Across all patients, a <FONT STYLE="white-space:nowrap">one-time</FONT> treatment of nex-z led to consistently rapid, deep and sustained serum TTR reduction,
regardless of baseline levels, through the latest <FONT STYLE="white-space:nowrap">follow-up.</FONT> All patients continued to show a sustained response with no evidence of a waning effect over time. Among the nine patients who reached 36 months of <FONT
STYLE="white-space:nowrap">follow-up,</FONT> the mean serum TTR reduction was 87% (mean absolute serum TTR level of 22.9 &micro;g/mL [mean 95% CI, 16.0 to 29.8]), consistent with the overall cohort at month 24. Based on multiple studies in ATTR
amyloidosis, low levels of serum TTR have been shown to lead to a meaningful clinical benefit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evidence of Stability or Improvement on Clinical and
Biomarker Measures in Phase 1 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients dosed with nex-z continued to show evidence of disease stabilization or improvement at month 24 compared to
baseline. Evaluation was based on multiple markers of cardiomyopathy, including <FONT STYLE="white-space:nowrap">N-terminal</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pro-B-type</FONT></FONT> natriuretic peptide
(NT-proBNP), high sensitivity Troponin T (hs-Troponin T), <FONT STYLE="white-space:nowrap">6-minute</FONT> walk test (6MWT), Kansas City Cardiomyopathy Questionnaire (KCCQ) and echocardiographic measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At 24 months, NT-proBNP and hs-Troponin T, which are markers known to be associated with disease progression, showed stability or improvement in 70% and 85%
of patients, respectively. Preservation of functional status, as measured by 6MWT, was observed with 69% of patients either showing stability or improvement. Notably, 81% of patients were stable or improved in their NYHA classification at 24 months,
including improvement in 83%&nbsp;of patients with NYHA Class&nbsp;III.<B> </B>There also was evidence of benefit in quality of life, regardless of NYHA Class&nbsp;at baseline as assessed by KCCQ. Assessment of cardiac structure with
echocardiography showed a similar pattern of stability with limited progression of cardiac remodeling at 24 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Post-Hoc</FONT> Mortality Assessment of Phase 1 Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, findings from a mortality assessment were presented. This <FONT STYLE="white-space:nowrap">post-hoc</FONT> analysis was conducted on a cohort of
1,792 <FONT STYLE="white-space:nowrap">ATTR-CM</FONT> patients from the National Amyloidosis Center (NAC) whose baseline characteristics were matched to those of the Phase 1 nex-z population. The analysis showed patients receiving a <FONT
STYLE="white-space:nowrap">one-time</FONT> treatment with nex-z had an <FONT STYLE="white-space:nowrap">all-cause</FONT> mortality rate of 3.9 per 100 patient-years, while the matched cohort had an <FONT STYLE="white-space:nowrap">all-cause</FONT>
mortality rate of 12.7 per 100 patient-years (HR 0.27, p=0.009). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 2 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phase 1 Safety </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nex-z was generally well tolerated across all patients in the Phase 1 clinical trial. The most commonly reported treatment-related adverse events were
infusion-related reactions (IRRs) and transaminase elevations. In this Phase 1 population, liver enzyme elevations did not exceed Grade 2. Through the long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> evaluation, including patients who
reached 44 months, any event leading to death (n=4) was related to the progression of the patients&#8217; underlying cardiovascular disease, consistent with what is expected for this patient population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AHA data presentation will be available on the Scientific Publications&nbsp;&amp; Presentations section of <U>intelliatx.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About</B><B></B><B>&nbsp;nex-z</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Based on Nobel <FONT
STYLE="white-space:nowrap">Prize-winning</FONT> CRISPR/Cas9 gene editing technology, nex-z has the potential to become the first <FONT STYLE="white-space:nowrap">one-time</FONT> treatment for transthyretin (ATTR) amyloidosis with cardiomyopathy <FONT
STYLE="white-space:nowrap">(ATTR-CM)</FONT> and/or polyneuropathy (ATTRv-PN). Nex-z is designed to inactivate the TTR gene that encodes for the transthyretin (TTR) protein. Interim Phase 1 clinical data showed the administration of nex-z led to
consistent, deep and long-lasting TTR reduction. This investigational product is being investigated in the ongoing MAGNITUDE and <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> Phase 3 clinical trials in
<FONT STYLE="white-space:nowrap">ATTR-CM</FONT> and ATTRv-PN, respectively, which are currently on clinical hold by the U.S. Food and Drug Administration (FDA). Further information about the clinical hold can be found <U>here</U>. Nex-z has received
Orphan Drug and RMAT Designations from the FDA and an Orphan Drug Designation (ODD) from the European Commission. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization
collaboration with Regeneron Pharmaceuticals, Inc.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Transthyretin (ATTR) Amyloidosis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transthyretin amyloidosis, or ATTR amyloidosis, is a rare, progressive and fatal disease. Hereditary ATTR (ATTRv) amyloidosis occurs when a person is born with
mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a propensity to misfold. These damaged proteins build up as amyloid in the body, causing serious complications in multiple tissues,
including the heart, nerves and digestive system. ATTRv amyloidosis predominantly manifests as polyneuropathy <FONT STYLE="white-space:nowrap">(ATTRv-PN),</FONT> which can lead to nerve damage, or cardiomyopathy
<FONT STYLE="white-space:nowrap">(ATTRv-CM),</FONT> which can lead to heart failure. Some individuals without the genetic mutation produce <FONT STYLE="white-space:nowrap">non-mutated,</FONT> or wild-type TTR proteins that become unstable over time,
misfolding and aggregating in disease-causing amyloid deposits. This condition, called wild-type ATTR (ATTRwt) amyloidosis, primarily affects the heart. There are an estimated 50,000 people worldwide living with ATTRv amyloidosis and between 200,000
and 500,000 people with ATTRwt amyloidosis. There is no known cure for ATTR amyloidosis and currently available medications are limited to slowing accumulation of misfolded TTR protein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 3 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Intellia Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The
company&#8217;s<I>&nbsp;in vivo</I>&nbsp;programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia&#8217;s<I>&nbsp;ex vivo</I>&nbsp;programs use CRISPR to engineer human cells outside the body
for the treatment of cancer and autoimmune diseases. Intellia&#8217;s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of
gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at&nbsp;<U>intelliatx.com</U> and follow us <U>@intelliatx</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
&#8220;forward-looking statements&#8221; of Intellia Therapeutics, Inc. (&#8220;Intellia&#8221; or the &#8220;Company&#8221;) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but
are not limited to, express or implied statements regarding Intellia&#8217;s beliefs and expectations regarding: the safety, efficacy, success and advancement of its clinical programs for nexiguran ziclumeran or &#8220;nex-z&#8221; (f/k/a
NTLA-2001), for transthyretin (&#8220;ATTR&#8221;) amyloidosis, including the ability to address the clinical hold that the United States Food and Drug Administration (&#8220;FDA&#8221;) placed on the investigational new drug (&#8220;IND&#8221;)
applications for our global Phase 3 MAGNITUDE study for ATTR amyloidosis with cardiomyopathy <FONT STYLE="white-space:nowrap">(&#8220;ATTR-CM&#8221;)</FONT> and our global Phase 3 <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> study for
hereditary ATTR amyloidosis with polyneuropathy (&#8220;ATTRv-PN&#8221;), and to resume those clinical trials; and its belief that greater TTR reduction may lead to greater clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs of future events and are subject to a
number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related
to Intellia&#8217;s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia&#8217;s relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies&#8217; evaluation of regulatory filings and other information related to our product
candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical
trials, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 4 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
risks related to our ability to address the clinical hold that the FDA placed on the IND applications for the MAGNITUDE Phase 3 study for <FONT STYLE="white-space:nowrap">ATTR-CM</FONT> and the <FONT
STYLE="white-space:nowrap">MAGNITUDE-2</FONT> Phase 3 study for ATTRv-PN and to resume those clinical trials; the risk that any one or more of Intellia&#8217;s product candidates, including nex-z, will not be successfully developed and
commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia&#8217;s other product candidates; and risks
related to Intellia&#8217;s reliance on collaborations, including that its collaboration with Regeneron will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of
which could cause Intellia&#8217;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in Intellia&#8217;s most recent annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and quarterly form on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in Intellia&#8217;s other filings with the
Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellia Contacts: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason Fredette </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and Corporate
Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jason.fredette@intelliatx.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media:</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Matt Crenson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ten Bridge Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@intelliatx.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mcrenson@tenbridgecommunications.com
</U></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 5 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ntla-20251108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/11/2025 2:15:32 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:ntla="http://intelliatx.com/20251108"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://intelliatx.com/20251108"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ntla-20251108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ntla-20251108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ntla-20251108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/11/2025 2:15:32 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ntla-20251108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/11/2025 2:15:32 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ntla-20251108.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g12611g1111003715793.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12611g1111003715793.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !M FX# 2(  A$! Q$!_\0
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M@ HHHH **** *EWJ=G8NJW,XC9AD @\U8BE2>))8VW(XW*?45R/C+_C\M_\
MKG_6NBTMUBT*UD<X58%8GT %4UI<E/6Q?HJA!K6G7"2/'<J5B&7+*5 _,567
MQ/I32[//8<XW%#BE9CNC8HJ&:[@M[4W4L@$( )<#(P>G2N(US5!>:GF"Y=[4
M;<#D#WX-"5Q2E8[VBJ5EJUC?N8[:?S'5<D;&''XBG7VIVFG*#<RA2?NJ!DG\
M*5F.Z+=%8L7BK3)9 A>2//\ $Z<?I6RK*ZAE(*D9!!X--IH$T]C/D>X%RP6Z
MD5=WW19L1_WU_6HM>U&[TZ")[2QNKMF;!6W4,5&.IS5.YMM.;4G=['=*9,E]
MTW)]>%Q^M7=;61H(O+BCD.[D/Y?''^W2DFU9%4Y14KR5T2:+>W%_8>==6EQ:
MR;R/+G4!L<<\=JT:S]'#BQQ)&D;;SPFS'_CO%9EHTG]N8.LK*OF-_H^3[\?A
M0D[:A.47*\59'1T5%<7$-K$99Y%CC'5F-9;>*=*5L"5V]Q&:=FR6TC9HJO:7
MUM?1^9;3+(HZXZCZBK%(84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!QWC+_C\M_\ KG_6MRV_Y%9/^O3_ -EK#\9?\?EO_P!<_P"M;EM_R*R?]>G_
M ++5O9$+XF<AHFG_ -I:AY#LPA WN >N/_UUK^(M#L[/3UN+6,QLK ,-Q.0?
MK4'@_P#Y",__ %S_ *UM>*?^0(_^^M-M\Q*2Y2OX<5-0\/O;7(,D2R%-I)''
M![5S^MV<%GK)MX(]D0V_+DGJ/>N@\'?\@N;_ *['_P!!%8WB?Y-?9CTVH?TH
M7Q _A1UMGI5CI[-+;0^6Q7#'>QX_$UQD4D6KZXTU_,L4))8[FQP.BBN\W)/;
MX1P1(G!!ZBO/]-@M1JWV?4EPF2ARQ&UO>E'J.70V-8MM#DT]VM);=)XQE0C_
M 'O;'>K7A"[:6RFMG)/DL"N?0]OS!_.GW6B:%96QGG0K&.G[P\_3GFI]!33"
MDTNFQR*I(5B^>?S^M#>@TGS'/7_@MKK7I;_-[AYO,^6X0+U],9Q74:O=?988
MV\U(\MC+PF3/X"H)[16O6?[=(N7SL%N"![9Q5K5'=(HRDXA^;J4=L_\ ?)%9
MQA&#NEN;U*]2JDIN]MA=*N/M-GYGF*_S$96(H/R-<CI__(W?]O#_ ,S78::S
M/:Y:82G<?F"LOZ,<UQ^G_P#(W?\ ;P_\S6BZF$NAV&I64-]:&*XD*1!@S$''
M3WK'>+PO'&8BT/ID,S'\Q53QA<2_:(+;<1%MWD=B<U>M-$T>'38[B=5D!0,T
MCN<=*%H@>K,;P_*MOXB\J&0M"Y90?[P[?TKNJX#1FC;Q+&T0VQ&1M@]!SBN_
MI3W"&P4445)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:M>%89"#,V"%/K7;:&K+HMJK @A.01[FM"BNYRNCQ%&SN4M84MH]VJ@DF(X
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MB/9:I:_UOW14U%[V+3II+"*.6Z5<HDG1CW%</?;];O=-DT_0KRQU5)U>>X:
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001652130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  08,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INTELLIA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4785571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40 Erie Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">285-6200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock (Par Value $0.0001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NTLA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d12611d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d12611d8k.htm">d12611d8k.htm</File>
    <File>ntla-20251108.xsd</File>
    <File>ntla-20251108_lab.xml</File>
    <File>ntla-20251108_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d12611d8k.htm": {
   "nsprefix": "ntla",
   "nsuri": "http://intelliatx.com/20251108",
   "dts": {
    "inline": {
     "local": [
      "d12611d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ntla-20251108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ntla-20251108_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ntla-20251108_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-11-08_to_2025-11-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d12611d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-11-08_to_2025-11-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d12611d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://intelliatx.com//20251108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-274596-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-274596-xbrl.zip
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MA@Q+6%T;]CWR6"C'L1-Q5WAQZ$Q9""(9#J8T@G[!ZP/!E).D<YQ!FIB(H9^
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MPO#$[&3WM'NR>]DM$%#8O0.[K]"S1DZM^TLP4=$Q[@('WW:.]>LL90ZQ"KE
MG!M^^L"NK\[>U6;MSNMV>]:&/WM[^V_:!V\.]UM_1#.\</RN-KKX<%$K\_9U
MZ^#-P>M#&1P;F;1;[8.#@]?P@69R^: %"NFDC\5J>R#@]1!>>9[D;#P7,8]$
MFDA'L<M8*%@#+T(E$[D0\"+TA,LNYUP)UM[ML#Y/. NG;!0&BW"6QCS(1'4'
MDY_@!/^0CI?Z @FH>TA,\_L.DP&[Y(FD,]S*9,X^BEBX,N'QDO6"F0R%*WQ^
M'\6/PO3N>;@0_D3$6@O?-EAGKW.P*NI\Q]<_J-(,G43O=#2P6YU>7/4'5TWP
M!Z/>Y?7@R+ZXD\S5,]68WN9=;:_&S@:CT66OWQ^>?\C>7U_VSNS[K\/^^..[
M&EC!RYJFYXJI9.D)]H[5(CX3S4DL^$U3!DJZXH@O0NF:A7U[\<'+_%#C_LJ7
M^R]K[(L1/3 E4P/MG7YYT7YUN.FR]LIE&VY0W*B\%H53^M:PEY6%P[8KR ,Y
MW3T9=OM"1 W@&9\ TWC@,A<L"E^#UJ9.(L- H4[?<+#5FUC RW"B1+P DSS9
M'79)F^A8\,\5_H,*45+K9P7[?ZU@/3\,9FR_PZ+,+<Y#T"Y'2%0BS@[VF#]C
M;@CN';RZ<:2,*WSGHJ]WTB2<3H^>U>UAZM;>NTO?.G]U?=MOL_KAFY<[[!8"
M+^-)PIV;YC06VKN!>LV:$,!]%L5A-%]Z_)M4K#X:7^[H1<]:]JQE#]"RSBM6
M?W.P3<M.WE^<CS, /I>):*J(.^(H"&\!Z]:ZH&^T^F075W;A#C%LPCS!5<*4
M6(B @=M,YJ"::52M)"$Z4/W)SAT:^@SKGA6T%':3.>1,[7+H#2'?E0'@N>66
M*(PI#&5;G09K[]VEX=7*#^CXL]X^H\5[U?8,/I)!*ABX/)-H@'+>"L^#^WB0
M:R>@K8I/1;+$"#Z5P%M*L],(+TGFJ*!+P6."CT;O'Z*MT]#SPMMF&EEU12T/
M0A8 N3EHB*6Z@7S(A4WE5-Z= SUA.:5[UOMT>C7L?Q@TV">N5*O!(-=OL3V;
MX]<_C"Y.!^Q\\/7ZZ_!JL%.M_/+B;:?=/F8;RRX-^-AIL?IY[[K?^_L1.Q^/
M>CL-8#P$)%>"'W$\&4B'>TU(%&>"S40@&%8UZ+O0CWBP!(*=5 %+P@#\RB+T
M4DP>Y7=<XL-:1P9&5&=7P^O+J^:$X^J$R) ":$A"EZ-4J0($7T6V!&3OKM.!
M:1SZ0%JDZT(</-E221(W^+22JZM65AR<A)//8NZSNC_;64LYP.^AOS3G(8:]
M.8:-@UF(A\@K4!D]22SA7[@N*I5\YGG)A^<EG_K'WF"GA7Q7F%VKU,/UZ%S5
MG,,%N ^']#J&+0T3.++0\ 7@ 5+7\T4,]P[8&2BLF-$!>O JGBT;U4I/)7.?
M:^O^A?L1R-OWTR#TPMF2U7MGO=YP1VM(+PA2N-&U([4N.^R3$"1/(.,B]D#]
MPP9[[T&T<'GKJ>N#7>1V9^]XC$?-.*_%G<:H(TRE413&"0O3F$V$)\44^,&3
M:L6*SPE3SR7I>0)T'*.;*Z:H=<@W8#Z(2_#$1X> QU,.J'^#;@QVH;AT<^/
M,B19.;F!LSG>;?!-0":*^G@Q!7X!27\+YP$;B3#@L0N&V.JWF#G'UZTNZ5YH
MF#FBAO5$2/X"@:'/_P!Q@.<+I]7*MG3ZWAN$@6@FP'^[_>;\V_H+&3A>2CX
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MW0MT"ZM>P!Z *6_W#H[M/75<S6ZK&9>?]\=Y5A^-WW\V'C?@*D1HM0QFX#.
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MDP^C8D+73D&<D!0YP [L^AQGTRHY3?3.!$5\H#D65EFJ%:O .(AC-<A^5B3
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MGYR^NW[ZY(DE<?*Y^P<*HS4UPOAUU<P_=\WCTD\XX H*B*UO?H2Z=\>1'W/
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M@?_Y]Z/!Y?LW*S#])RM6GG.1Y;-(B3=B)9%CU1VF2G[JZCC3H=J15]@3]^#
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M^&A)-+(QO\R\517 />;.N6A=G@6G T3?S(O(,_5=L=1O9W<'#]5V]3L]]I]
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MP9&',%,ULC#0<M4.\Y7O[-1N&73**P8=D15!0%-RT+#M^SZ<D+.4(: ,5^3
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M$_2/86C(/Y5L"7A=!K@ 70@7=FP#=:C;N4#$//UY^$;<"OY 6=CPMDZ5QDL
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MH0,AZDOP6=L.Y/^P%7(9[:7F%@OL0Z_K(_;%/L*))?\ 4$L! A0#%     @
M$HMJ6X53/33\(0  ZJ\   T              ( !     &0Q,C8Q,60X:RYH
M=&U02P$"% ,4    "  2BVI;Y+]-PMX5   ^7@  $               @ $G
M(@  9#$R-C$Q9&5X.3DQ+FAT;5!+ 0(4 Q0    ( !*+:EOS]DM,)Q@  '-?
M   0              "  3,X  !D,3(V,3%D97@Y.3(N:'1M4$L! A0#%
M  @ $HMJ6UDS>!<] P  10L  !$              ( !B%   &YT;&$M,C R
M-3$Q,#@N>'-D4$L! A0#%     @ $HMJ6[BN_4UY!@  N$8  !4
M     ( !]%,  &YT;&$M,C R-3$Q,#A?;&%B+GAM;%!+ 0(4 Q0    ( !*+
M:EOG8HQ!P00  #HL   5              "  :!:  !N=&QA+3(P,C4Q,3 X
>7W!R92YX;6Q02P4&      8 !@!\ 0  E%\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d12611d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ntla-20251108.xsd" xlink:type="simple"/>
    <context id="duration_2025-11-08_to_2025-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
        </entity>
        <period>
            <startDate>2025-11-08</startDate>
            <endDate>2025-11-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-368">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-11-08_to_2025-11-08"
      id="Hidden_dei_EntityCentralIndexKey">0001652130</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-379">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-380">2025-11-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-381">INTELLIA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-382">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-383">001-37766</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-384">36-4785571</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-385">40 Erie Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-386">Suite 130</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-387">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-388">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-389">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-390">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-391">285-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-392">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-393">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-394">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-395">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-396">Common Stock (Par Value $0.0001)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-397">NTLA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-398">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-11-08_to_2025-11-08" id="ixv-399">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
